Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine for reduction of daily life pain in sickle cell disease
NL-OMON39603Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Frequency of sickle cell-related pain in daily life. Started Apr 2013; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON39603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39603.